This first-of-its-kind solution delivers end-to-end single-cell analysis in an intuitive web-based interface

SAN DIEGO, CA – March 2, 2021 – ROSALIND, a leader in extracting meaningful insights from diverse pools of life science data, today announced the commercial launch of its new solution for single cell data analysis. The new analysis module, which enables web-based collaboration and the analysis and interpretation of 10X Genomics-generated single cell data, is built on the company’s proven cloud-based platform that is well-known for its intuitive, fast, and easy-to-use tools for analyzing RNA-Seq, NanoString nCounter, as well as other data types. Formerly known as OnRamp Bio, ROSALIND also unveiled its new corporate brand as part of its presence at the virtual Advances in Genome Biology and Technology (AGBT) conference taking place March 1-3, 2021.

“In recent years, enabled by the broad adoption of powerful new technology platforms, single cell analysis has begun to revolutionize biological understanding and translational applications. However, many researchers are encountering challenges with the computational burdens of basic single-cell analysis and a lack of intuitive bioinformatics tools,” said Jean Lozach, Chief Science Officer at ROSALIND. “The ROSALIND Single Cell module makes it possible for any researcher to analyze and interpret single cell data via a web browser. Democratizing access has the potential to dramatically accelerate discovery and insights from single cell science.”

The ROSALIND platform is a cloud-based SaaS ecosystem accessible via any secure web browser. Its intuitive pipelines for the analysis and interpretation of multi-omic data enable point-and-click discovery in RNA-Seq, Single Cell RNA-Seq, ATAC-Seq, and ChIP-Seq, among others. The new ROSALIND Single Cell Solution enables users to easily generate and annotate single cell clusters from FASTQ data files via an intuitive graphical user interface, then perform downstream analysis of cell clusters informed by knowledge bases and comparisons to other data sets. With the proven ROSALIND platform, users benefit from the collaboration capabilities and scalability of an elastic cloud-based computing infrastructure as well as enterprise security and project permissions management.

“ROSALIND has become a must-have platform enabling the last mile of discovery. Today’s researchers require a powerful yet easy-to-use data analysis ecosystem that enables them to focus on scientific discoveries by conveniently scaling cloud computing resources, integrating multi-omic datasets, and facilitating global data sharing and collaboration. With the launch of our new single cell module, we have replicated what we successfully accomplished in bulk RNA-Seq to bring scientists the tools they need to keep pace with the rapidly expanding landscape of single cell science,” said Tim Wesselman, CEO of ROSALIND. “The company was founded to simplify the practice of data interpretation so that any biologist, researcher or drug developer, no matter their level of bioinformatics expertise, could harness the potential of genomic information. ROSALIND was named in honor of Dr. Rosalind Franklin, the pioneering molecular biologist whose passion for science and significant contributions to our understanding of DNA helped pave the way for the revolution in life science research that we are privileged to be part of today. At ROSALIND, we aim to support new breakthrough discoveries and to honor the scientists who make this possible so that we can revolutionize precision medicine together by unifying the analysis of complex datasets and unlocking new frontiers for biomarker discovery and a greater understanding of biology.”

ROSALIND CEO Tim Wesselman will present an overview of the platform and new single cell module at the AGBT conference on Tuesday, March 2, 2021 between 3:00 – 3:15pm ET. More information and event access can be found at To learn more about the ROSALIND platform, please visit:


Based in San Diego, ROSALIND enables the world’s life science researchers to derive more value from their data and complete projects faster. We believe the potential of biomedical and multi-omic data is maximized when it is accessible, interactive, and shareable. Extracting meaningful insights from pools of data takes a truly interoperable ecosystem that breaks down silos of complex information and sparks collaboration. The ROSALIND platform harnesses the power of scientific collaboration, cloud-computing, and data science, to enable integrated analyses that unify knowledge through an intuitive user interface that is built for any researcher. By connecting high-value datasets with the researchers, knowledge bases, and best-in-class analysis methods that maximize their potential, ROSALIND users are able to discover meaningful insights faster. For more information, please visit


Media Contact:

Colin Sanford

TRY ROSALIND: Free 14 Day Trial

Related Posts

Jay Gerlach

Written by Jay Gerlach

Jay is Vice President of Strategic Marketing and Alliances at Rosalind. He is passionate about leveraging new technologies to accelerate discovery of new diagnostics and treatments. Previously, he served as Senior Director of Product Management and Business Unit Leader for NanoString’s nCounter business. At NanoString, he led development and commercialization of many new products and also designed and implemented new processes to help the company scale from a small start-up to a public company. Prior to NanoString, Jay worked at PATH in a role focused on establishing public-private partnerships for development of diagnostic tests for infectious diseases in low resource settings around the world. Early in his career he performed genomic and proteomic research at University of Washington, Seattle Biomed, and Ambit Biosciences.